Differences in the disposition of silymarin between patients with nonalcoholic fatty liver disease and chronic hepatitis C.
about
Silymarin for HCV infectionLiver fibrosis and protection mechanisms action of medicinal plants targeting apoptosis of hepatocytes and hepatic stellate cellsThe effects of milk thistle (Silybum marianum) on human cytochrome P450 activity.Effect of caloric restriction and AMPK activation on hepatic nuclear receptor, biotransformation enzyme, and transporter expression in lean and obese mice.Association of markers of chronic viral hepatitis and blood mercury levels in US reproductive-age women from NHANES 2001-2008: a cross-sectional study.Hepatoprotective and antiviral functions of silymarin components in hepatitis C virus infection.HiFSA fingerprinting applied to isomers with near-identical NMR spectra: the silybin/isosilybin caseAn assessment of pharmacokinetics and antioxidant activity of free silymarin flavonolignans in healthy volunteers: a dose escalation study.Silymarin induces insulin resistance through an increase of phosphatase and tensin homolog in Wistar rats.Recent advances in the herbal treatment of non-alcoholic Fatty liver disease.Protective mechanisms of medicinal plants targeting hepatic stellate cell activation and extracellular matrix deposition in liver fibrosis.Non-alcoholic Fatty Liver Disease: Beneficial Effects of Flavonoids.Effects and tolerance of silymarin (milk thistle) in chronic hepatitis C virus infection patients: a meta-analysis of randomized controlled trials.Quercetin treatment ameliorates inflammation and fibrosis in mice with nonalcoholic steatohepatitis.
P2860
Q26851453-F9D4DD35-F0E0-4B56-A710-A637B23ABC64Q30369750-1F1D19CE-F0B8-4F12-AD1D-F598FB85E0B8Q34185982-B531FC57-3930-47CC-96A5-B2E5FEA0B5BAQ34478741-075C4A10-4707-40C9-A9FA-FFCA9043AA8FQ36439086-0BE76FAE-870B-4908-8F72-08C8DF4E6226Q36675737-2C3D9334-8586-4C91-9F4E-2C5873F8B82AQ36807240-F674921E-A3F5-444E-B1FB-1B8BACBE319DQ37422723-A88DFF84-7335-425B-B70B-071E3F5EC14EQ37431571-9F6916F8-0BF8-45CA-9D52-18E5BFE37FF7Q37585296-CD6944B1-F8B1-49B3-9749-85550A61008EQ38326327-135D1282-9215-446C-94B2-A433C6EF5F89Q38866384-26497BF2-46B2-458A-B9B1-F7D23478B0A7Q41729153-D083B036-60C9-4DCF-819A-BA61B60956C3Q45031991-429BEE5F-096D-4132-9F21-37AA3DCAAB4D
P2860
Differences in the disposition of silymarin between patients with nonalcoholic fatty liver disease and chronic hepatitis C.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Differences in the disposition ...... sease and chronic hepatitis C.
@ast
Differences in the disposition ...... sease and chronic hepatitis C.
@en
type
label
Differences in the disposition ...... sease and chronic hepatitis C.
@ast
Differences in the disposition ...... sease and chronic hepatitis C.
@en
prefLabel
Differences in the disposition ...... sease and chronic hepatitis C.
@ast
Differences in the disposition ...... sease and chronic hepatitis C.
@en
P2093
P2860
P50
P356
P1476
Differences in the disposition ...... sease and chronic hepatitis C.
@en
P2093
Catherine M Meyers
Edward Doo
Michael W Fried
Philip C Smith
Roy L Hawke
Sarah J Schrieber
Steven H Belle
Victor J Navarro
Zhiming Wen
P2860
P304
P356
10.1124/DMD.111.040212
P577
2011-08-24T00:00:00Z